肌少症与肌脂肪变性对可切除胰腺导管腺癌患者的预后价值
该研究回顾性纳入347例接受根治性手术的可切除胰腺导管腺癌患者,利用人工智能在术前CT门静脉期L3椎体下终板层面自动分割肌肉,评估肌少症和肌脂肪变性。结果显示肌脂肪变性(mMT)与较差的总生存期(OS)和无复发生存期(RFS)显著相关,而单纯肌少症(sMT)与预后无关。
要点
- 肌脂肪变性是可切除PDAC术后不良OS和RFS的独立预后因素。
- 单纯肌少症与OS和RFS无显著关联,提示肌肉质量比肌肉数量更重要。
- 术前CT L3层面自动肌肉分割可评估肌脂肪变性,辅助风险分层。
诊断标准与关键数值
- 肌少症和肌脂肪变性的诊断截断值采用Contal和O'Quigley方法确定。
临床应用与阅片要点
- 术前CT评估L3层面肌肉质量(尤其是肌脂肪变性)有助于识别PDAC术后高危患者,可考虑纳入影像报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The clinical relevance of myosteatosis has not been well evaluated in patients with pancreatic ductal adenocarcinoma (PDAC), although sarcopenia has been extensively researched. Therefore, we evaluated the prognostic value of muscle quality, including myosteatosis, in patients with resectable PDAC treated surgically.
MATERIALS AND METHODS: We retrospectively evaluated 347 patients with resectable PDAC who underwent curative surgery (mean age ± standard deviation, 63.6 ± 9.6 years; 202 male). Automatic muscle segmentation was performed on preoperative computed tomography (CT) images using an artificial intelligence program. A single axial image of the portal phase at the inferior endplate level of the L3 vertebra was used for analysis in each patient. Sarcopenia was evaluated using the skeletal muscle index, calculated as the skeletal muscle area (SMA) divided by the height squared. The mean SMA attenuation was used to evaluate myosteatosis. Diagnostic cutoff values for sarcopenia and myosteatosis were devised using the Contal and O'Quigley methods, and patients were classified according to normal (nMT), sarcopenic (sMT), myosteatotic (mMT), or combined (cMT) muscle quality types. Multivariable Cox regression analyses were conducted to assess the effects of muscle type on the overall survival (OS) and recurrence-free survival (RFS) after surgery.
RESULTS: Eighty-four (24.2%), 73 (21.0%), 75 (21.6%), and 115 (33.1%) patients were classified as having nMT, sMT, mMT, and cMT, respectively. Compared to nMT, mMT and cMT were significantly associated with poorer OS, with hazard ratios (HRs) of 1.49 (95% confidence interval, 1.00-2.22) and 1.68 (1.16-2.43), respectively, while sMT was not (HR of 1.40 [0.94-2.10]). Only mMT was significantly associated with poorer RFS, with an HR of 1.59 (1.07-2.35), while sMT and cMT were not.
CONCLUSION: Myosteatosis was associated with poor OS and RFS in patients with resectable PDAC who underwent curative surgery.
引用
- Kim, Ahn, Kim, et al. Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Korean J Radiol. 2022. PMID: 36098341. doi:10.3348/kjr.2022.0277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。